# PROTEUS (NCT03767244)

> A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03767244
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Prostatic Neoplasms
- Interventions: Apalutamide; Androgen Deprivation Therapy (ADT); Placebo
- Enrollment: 2517
- Primary outcome: Percentage of Participants with Pathologic complete response (pCR)
- Primary outcome: Metastasis-Free Survival (MFS)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=proteus-nct03767244